Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
B-cell Malignancy · Non-Hodgkin Lymphoma · Mantle Cell Lymphoma · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Waldenström Macroglobulinemia · Marginal Zone Lymphoma · Follicular Lymphoma · DLBCL Unclassifiable · Richter's Transformation
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 146 (planned)
- Started
- May 6, 2022
- Main results expected
- Jun 30, 2027
- Fully finished
- Jan 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Measured over: From first dose of the study drug(s) to 30 days after the last dose or before initiation of a new anticancer therapy, whichever occurs first (up to approximately 3 years)
Phase 1: Recommended Phase 2 dose (RP2D) of Tacabrutideg
Measured over: From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)
Phase 1a: Maximum tolerated dose (MTD) of Tacabrutideg
Measured over: From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)
Phase 2: Overall Response Rate (ORR) in participants with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Measured over: Up to approximately 3 years
Phase 2: ORR in participants with R/R Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Measured over: Up to approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05294731 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC